Cerus Corporation is adjusting its previously stated product revenue guidance range. The Company expects full-year 2023 product revenue to be in the range of $155 million to $158 million. The revision is due in part to the delay in signing the now executed IFC sales agreement with one of the largest U.S. producers of cryoprecipitate.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.73 USD | -9.42% | +6.79% | -19.91% |
05-02 | Transcript : Cerus Corporation, Q1 2024 Earnings Call, May 02, 2024 | |
05-02 | Earnings Flash (CERS) CERUS CORPORATION Posts Q1 Revenue $43.4M, vs. Street Est of $38.4M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.91% | 353M | |
+10.39% | 126B | |
-6.86% | 10.93B | |
+2.52% | 9.11B | |
+38.96% | 5.42B | |
-17.50% | 5.18B | |
+8.36% | 3.44B | |
-8.84% | 2.8B | |
-7.52% | 2.25B | |
-3.00% | 2.21B |
- Stock Market
- Equities
- CERS Stock
- News Cerus Corporation
- Cerus Corporation Provides Product Revenue Guidance for the Full-Year 2023